Outcomes After Stereotactic Lung Radiotherapy or Wedge Resection for Stage I Non–Small-Cell Lung Cancer
Top Cited Papers
- 20 February 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (6), 928-935
- https://doi.org/10.1200/jco.2009.25.0928
Abstract
Purpose: To compare outcomes between lung stereotactic radiotherapy (SBRT) and wedge resection for stage I non–small-cell lung cancer (NSCLC). Patients and Methods: One hundred twenty-four patients with T1-2N0 NSCLC underwent wedge resection (n = 69) or image-guided lung SBRT (n = 58) from February 2003 through August 2008. All were ineligible for anatomic lobectomy; of those receiving SBRT, 95% were medically inoperable, with 5% refusing surgery. Mean forced expiratory volume in 1 second and diffusing capacity of lung for carbon monoxide were 1.39 L and 12.0 mL/min/mmHg for wedge versus 1.31 L and 10.14 mL/min/mmHg for SBRT (P = not significant). Mean Charlson comorbidity index and median age were 3 and 74 years for wedge versus 4 and 78 years for SBRT (P < .01, P = .04). SBRT was volumetrically prescribed as 48 (T1) or 60 (T2) Gy in four to five fractions. Results: Median potential follow-up is 2.5 years. At 30 months, no significant differences were identified in regional recurrence (RR), locoregional recurrence (LRR), distant metastasis (DM), or freedom from any failure (FFF) between the two groups (P > .16). SBRT reduced the risk of local recurrence (LR), 4% versus 20% for wedge (P = .07). Overall survival (OS) was higher with wedge but cause-specific survival (CSS) was identical. Results excluding synchronous primaries, nonbiopsied tumors, or pathologic T4 disease (wedge satellite lesion) showed reduced LR (5% v 24%, P = .05), RR (0% v 18%, P = .07), and LRR (5% v 29%, P = .03) with SBRT. There were no differences in DM, FFF, or CSS, but OS was higher with wedge. Conclusion: Both lung SBRT and wedge resection are reasonable treatment options for stage I NSCLC patients ineligible for anatomic lobectomy. SBRT reduced LR, RR, and LRR. In this nonrandomized population of patients selected for surgery versus SBRT (medically inoperable) at physician discretion, OS was higher in surgical patients. SBRT and surgery, however, had identical CSS.Keywords
This publication has 19 references indexed in Scilit:
- Stereotactic Body Radiation Therapy for Early-Stage Non–Small-Cell Lung Carcinoma: Four-Year Results of a Prospective Phase II StudyInternational Journal of Radiation Oncology*Biology*Physics, 2009
- Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional StudyJournal of Thoracic Oncology, 2007
- Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frameInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancerLung Cancer, 2005
- Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experienceInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Radiotherapy Alone for Medically Inoperable Stage I Non-Small–Cell Lung Cancer: The Duke ExperienceInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Hyperfractionated radiotherapy alone for clinical stage I nonsmall cell lung cancerInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Local irradiation alone for peripheral Stage I lung cancer: Could we omit the elective regional nodal irradiation?International Journal of Radiation Oncology*Biology*Physics, 1996
- Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancerThe Annals of Thoracic Surgery, 1995
- Radiation therapy in the management of medically inoperable carcinoma of the lungs: Results and implications for future treatment strategiesInternational Journal of Radiation Oncology*Biology*Physics, 1992